Insulet Corporation
Insulet Corporation develops insulin delivery systems for people with insulin-dependent diabetes. The companys Omnipod platform includes three products: Omnipod 5, Omnipod DASH, and Omnipod GO. Products are sold through distributors, pharmacies, and directly in various countries.
Overview
Strengths
- Consistent growth: revenue has compounded at 24.5% a year over 5 years, rising every year.
- ROIC of 23.1% beats 90% of its 51 Medical Devices peers (median 9.6%).
- Earnings are projected to grow at a solid rate (20.0% per year).
Weaknesses
- Unreliable cash generation: free cash flow was negative in 3 of the last 6 years.
- Our discounted cash flow target price (101.08 USD) is 35% below the current price.
- Valued at a premium to its Medical Devices peers: P/E 44.5x vs. a median of 29.4x.
Key Financial Data